Alkermes plc (NASDAQ:ALKS) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Alkermes plc (NASDAQ:ALKS) have received an average rating of “Moderate Buy” from the eighteen research firms that are presently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $44.0667.

Several brokerages have recently weighed in on ALKS. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Alkermes in a research report on Monday, December 29th. Wolfe Research assumed coverage on Alkermes in a report on Monday, February 23rd. They set an “outperform” rating and a $45.00 target price on the stock. Wall Street Zen cut Alkermes from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Truist Financial increased their price objective on shares of Alkermes from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Finally, Zacks Research lowered shares of Alkermes from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 19th.

Insider Activity

In other Alkermes news, Director Shane Cooke sold 61,200 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $34.57, for a total value of $2,115,684.00. Following the transaction, the director owned 103,744 shares in the company, valued at $3,586,430.08. The trade was a 37.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Christian Todd Nichols sold 6,000 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $30.00, for a total transaction of $180,000.00. Following the completion of the transaction, the senior vice president directly owned 109,769 shares of the company’s stock, valued at approximately $3,293,070. The trade was a 5.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 157,434 shares of company stock valued at $5,305,794 in the last 90 days. Company insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ALKS. Assetmark Inc. increased its holdings in Alkermes by 933.8% during the 3rd quarter. Assetmark Inc. now owns 827 shares of the company’s stock worth $25,000 after purchasing an additional 747 shares during the last quarter. Cullen Frost Bankers Inc. acquired a new stake in shares of Alkermes during the fourth quarter worth approximately $28,000. Johnson Financial Group Inc. bought a new stake in shares of Alkermes in the third quarter worth $31,000. UMB Bank n.a. increased its stake in shares of Alkermes by 57.6% in the fourth quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock worth $34,000 after buying an additional 446 shares during the last quarter. Finally, Salomon & Ludwin LLC raised its holdings in Alkermes by 115.6% in the fourth quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company’s stock valued at $35,000 after acquiring an additional 667 shares in the last quarter. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Alkermes Stock Down 3.2%

Alkermes stock opened at $28.35 on Friday. The firm has a fifty day moving average of $31.59 and a 200-day moving average of $30.23. Alkermes has a 52-week low of $25.17 and a 52-week high of $36.32. The firm has a market capitalization of $4.72 billion, a P/E ratio of 19.83, a PEG ratio of 7.30 and a beta of 0.53.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Wednesday, February 25th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.14). Alkermes had a net margin of 16.37% and a return on equity of 14.91%. The business had revenue of $384.55 million for the quarter, compared to analyst estimates of $380.44 million. During the same quarter in the previous year, the firm posted $1.05 EPS. The business’s revenue was down 10.6% compared to the same quarter last year. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. On average, research analysts expect that Alkermes will post 1.31 EPS for the current fiscal year.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.